サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1420998

医薬品・遺伝子送達システム市場：世界の業界分析、規模、シェア、量、成長、動向、および2023年～2031年予測

Drug and Gene Delivery Systems Market - Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 2023-2031
出版日: | 発行: Transparency Market Research | ページ情報: 英文 334 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.90円
医薬品・遺伝子送達システム市場：世界の業界分析、規模、シェア、量、成長、動向、および2023年～2031年予測
出版日: 2023年12月22日
発行: Transparency Market Research
ページ情報: 英文 334 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

医薬品・遺伝子送達システム市場 - レポートの範囲

世界の医薬品・遺伝子送達システム市場に関するTMRのレポートは、過去と現在の成長動向、および2023年から2031年の予測期間中に市場の指標の貴重な洞察を得る機会を研究しています。このレポートは、世界の医薬品の収益を提供します。 2023年を基準年、2031年を予測年として考慮した、2017年から2031年の期間の遺伝子送達システム市場。このレポートは、2023年から2031年までの世界の医薬品・遺伝子送達システム市場の複合年間成長率（CAGR %）も提供します。

このレポートは広範な調査を経て作成されました。1次調査では、調査活動の大部分が行われ、アナリストが主要なオピニオンリーダー、業界リーダー、オピニオンメーカーにインタビューを実施しました。2次調査には、医薬品・遺伝子送達システム市場を理解するために、主要企業の製品文献、年次報告書、プレスリリース、および関連文書の参照が含まれます。

市場スナップショット
2023年の市場価値 34億米ドル
2031年の市場価値 78億米ドル
CAGR 10%

このレポートは、世界の医薬品・遺伝子送達システム市場の競合情勢を詳しく調査しています。世界の医薬品・遺伝子送達システム市場で活動する主要企業が特定され、これらのそれぞれがさまざまな属性の観点からプロファイルされています。会社概要、財務状況、最近の動向、 SWOTは、このレポートで紹介されている世界の医薬品・遺伝子送達システム市場の企業の属性です。

目次

第1章 序文

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー：世界市場

第4章 市場概要

  • イントロダクション
  • 概要
  • 市場力学
  • 世界市場の分析と予測、2017年～2031年

第5章 重要な洞察

  • パイプライン分析
  • 主要配信システム/ブランド分析
  • 主な合併と買収
  • COVID-19感染症のパンデミックが業界に与える影響

第6章 世界市場の分析と予測：送達システム別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：送達システム別、2017年～2031年
    • ドラッグデリバリーシステム
      • 子宮内インプラント
      • プロドラッグインプラント
      • ポリマードラッグデリバリー
      • 標的ドラッグデリバリー
    • 遺伝子デリバリーシステム
      • ウイルス遺伝子の送達
        • アデノウイルスベクター
        • レンチウイルスベクター
        • レトロウイルスベクター
        • アデノ関連ウイルスベクター
        • センダイウイルスベクター
        • 単純ヘルペスウイルスベクター
        • その他
      • 非ウイルス遺伝子の送達
        • 天然有機化合物
        • 物理的方法
        • 化学的方法
      • 複合ハイブリッドシステム
  • 市場魅力分析：送達システム別

第7章 世界市場の分析と予測：投与経路別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：投与経路別、2017年～2031年
    • 経口
    • 注射
    • 吸入
    • 経皮
    • 眼科
    • 鼻
    • 局所
  • 市場魅力度分析：投与経路別

第8章 世界市場の分析と予測：用途別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：用途別、2017年～2031年
    • 感染症
    • 腫瘍学
    • 眼科
    • 泌尿器科
    • 糖尿病
    • 中枢神経系
    • その他
  • 市場魅力分析：用途別

第9章 世界市場の分析と予測：地域別

  • 主な調査結果
  • 市場金額予測：地域別、2017年～2031年
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場魅力度分析：地域別

第10章 北米市場の分析と予測

第11章 欧州市場の分析と予測

第12章 アジア太平洋市場の分析と予測

第13章 ラテンアメリカ市場の分析と予測

第14章 中東・アフリカ市場の分析と予測

第15章 競合情勢

  • 市場企業 - 競争マトリックス（企業の階層および規模別）
  • 市場シェア分析：企業別（2022年）
  • 企業プロファイル
    • Novartis AG
    • Amgen Inc.
    • Oxford BioMedica plc.
    • SIBIONO
    • Shanghai Sunway Biotech Co., Ltd.
    • F. Hoffmann-La Roche Ltd.
    • Pfizer, Inc.
    • Bayer AG
    • Johnson &Johnson Services, Inc.
    • Becton, Dickinson and Company
    • AstraZeneca plc
    • Baxter International, Inc.
    • Boston Scientific Corporation
    • GenVivo, Inc.
図表

List of Tables

  • Table 01: Global Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Delivery System, 2017-2031
  • Table 02: Global Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 03: Global Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Application, 2017-2031
  • Table 04: Global Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Region, 2017-2031
  • Table 05: North America Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Country, 2017-2031
  • Table 06: North America Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Delivery System, 2017-2031
  • Table 07: North America Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 08: North America Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Application, 2017-2031
  • Table 09: Europe Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 10: Europe Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Delivery System, 2017-2031
  • Table 11: Europe Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 12: Europe Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Application, 2017-2031
  • Table 13: Asia Pacific Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 14: Asia Pacific Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Delivery System, 2017-2031
  • Table 15: Asia Pacific Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 16: Asia Pacific Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Application, 2017-2031
  • Table 17: Latin America Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 18: Latin America Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Delivery System, 2017-2031
  • Table 19: Latin America Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 20: Latin America Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Application, 2017-2031
  • Table 21: Middle East & Africa Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 22: Middle East & Africa Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Delivery System, 2017-2031
  • Table 23: Middle East & Africa Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 24: Middle East & Africa Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Application, 2017-2031

List of Figures

  • Figure 01: Global Drug and Gene Delivery Systems Market Size (US$ Mn) and Distribution (%), by Region, 2022 and 2031
  • Figure 02: Global Drug and Gene Delivery Systems Market Revenue (US$ Mn), by Delivery System, 2022
  • Figure 03: Global Drug and Gene Delivery Systems Market Value Share, by Delivery System, 2022
  • Figure 04: Global Drug and Gene Delivery Systems Market Revenue (US$ Mn), by Route of Administration, 2022
  • Figure 05: Global Drug and Gene Delivery Systems Market Value Share, by Route of Administration, 2022
  • Figure 06: Global Drug and Gene Delivery Systems Market Revenue (US$ Mn), by Application, 2022
  • Figure 07: Global Drug and Gene Delivery Systems Market Value Share, by Application, 2022
  • Figure 08: Global Drug and Gene Delivery Systems Market Value Share, by Region, 2022
  • Figure 09: Global Drug and Gene Delivery Systems Market Value (US$ Mn) Forecast, 2023-2031
  • Figure 10: Global Drug and Gene Delivery Systems Market Value Share Analysis, by Delivery System, 2022 and 2031
  • Figure 11: Global Drug and Gene Delivery Systems Market Attractiveness Analysis, by Delivery System, 2023-2031
  • Figure 12: Global Drug and Gene Delivery Systems Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 13: Global Drug and Gene Delivery Systems Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 14: Global Drug and Gene Delivery Systems Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 15: Global Drug and Gene Delivery Systems Market Attractiveness Analysis, by Application, 2022-2031
  • Figure 16: Global Drug and Gene Delivery Systems Market Value Share Analysis, by Region, 2022 and 2031
  • Figure 17: Global Drug and Gene Delivery Systems Market Attractiveness Analysis, by Region, 2022-2031
  • Figure 18: North America Drug and Gene Delivery Systems Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 19: North America Drug and Gene Delivery Systems Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 20: North America Drug and Gene Delivery Systems Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 21: North America Drug and Gene Delivery Systems Market Value Share Analysis, by Delivery System, 2022 and 2031
  • Figure 22: North America Drug and Gene Delivery Systems Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 23: North America Drug and Gene Delivery Systems Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 24: North America Drug and Gene Delivery Systems Market Attractiveness Analysis, by Delivery System, 2023-2031
  • Figure 25: North America Drug and Gene Delivery Systems Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 26:North America Drug and Gene Delivery Systems Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 27: Europe Drug and Gene Delivery Systems Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 28: Europe Drug and Gene Delivery Systems Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 29: Europe Drug and Gene Delivery Systems Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 30: Europe Drug and Gene Delivery Systems Market Value Share Analysis, by Delivery System, 2022 and 2031
  • Figure 31: Europe Drug and Gene Delivery Systems Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 32: Europe Drug and Gene Delivery Systems Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 33: Europe Drug and Gene Delivery Systems Market Attractiveness Analysis, by Delivery System, 2023-2031
  • Figure 34: Europe Drug and Gene Delivery Systems Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 35: Europe Drug and Gene Delivery Systems Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 36: Asia Pacific Drug and Gene Delivery Systems Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 37: Asia Pacific Drug and Gene Delivery Systems Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 38: Asia Pacific Drug and Gene Delivery Systems Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 39: Asia Pacific Drug and Gene Delivery Systems Market Value Share Analysis, by Delivery System, 2022 and 2031
  • Figure 40: Asia Pacific Drug and Gene Delivery Systems Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 41: Asia Pacific Drug and Gene Delivery Systems Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 42: Asia Pacific Drug and Gene Delivery Systems Market Attractiveness Analysis, by Delivery System, 2023-2031
  • Figure 43: Asia Pacific Drug and Gene Delivery Systems Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 44: Asia Pacific Drug and Gene Delivery Systems Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 45: Latin America Drug and Gene Delivery Systems Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 46: Latin America Drug and Gene Delivery Systems Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 47: Latin America Drug and Gene Delivery Systems Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 48: Latin America Drug and Gene Delivery Systems Market Value Share Analysis, by Delivery System, 2022 and 2031
  • Figure 49: Latin America Drug and Gene Delivery Systems Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 50: Latin America Drug and Gene Delivery Systems Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 51: Latin America Drug and Gene Delivery Systems Market Attractiveness Analysis, by Delivery System, 2023-2031
  • Figure 52: Latin America Drug and Gene Delivery Systems Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 53: Latin America Drug and Gene Delivery Systems Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 54: Middle East & Africa Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 55: Middle East & Africa Drug and Gene Delivery Systems Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 56: Middle East & Africa Drug and Gene Delivery Systems Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 57: Middle East & Africa Drug and Gene Delivery Systems Market Value Share Analysis, by Delivery System, 2022 and 2031
  • Figure 58: Middle East & Africa Drug and Gene Delivery Systems Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 59: Middle East & Africa Drug and Gene Delivery Systems Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 60: Middle East & Africa Drug and Gene Delivery Systems Market Attractiveness Analysis, by Delivery System, 2023-2031
  • Figure 61: Middle East & Africa Drug and Gene Delivery Systems Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 62: Middle East & Africa Drug and Gene Delivery Systems Market Attractiveness Analysis, by Application, 2023-2031
目次
Product Code: TMRGL26135

Drug and Gene Delivery Systems Market - Scope of Report

TMR's report on the global drug and gene delivery systems market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global drug and gene delivery systems market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global drug and gene delivery systems market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the drug and gene delivery systems market.

Market Snapshot
Market Value in 2023US$ 3.4 Bn
Market Value in 2031US$ 7.8 Bn
CAGR10%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global drug and gene delivery systems market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global drug and gene delivery systems market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global drug and gene delivery systems market.

The report delves into the competitive landscape of the global drug and gene delivery systems market. Key players operating in the global drug and gene delivery systems market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global drug and gene delivery systems market profiled in this report.

Key Questions Answered in Global drug and gene delivery systems Market Report:

  • What is the sales/revenue generated by drug and gene delivery systems across all regions during the forecast period?
  • What are the opportunities in the global drug and gene delivery systems market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Drug and Gene Delivery Systems Market - Research Objectives and Research Approach

The comprehensive report on the global drug and gene delivery systems market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global drug and gene delivery systems market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global drug and gene delivery systems market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Drug and Gene Delivery Systems Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Delivery System Definition
    • 4.1.2. Industry Evolution/Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Drug and Gene Delivery Systems Market Analysis and Forecast, 2017-2031

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Delivery System/Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Drug and Gene Delivery Systems Market Analysis and Forecast, by Delivery System

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Delivery System, 2017-2031
    • 6.3.1. Drug Delivery Systems
      • 6.3.1.1. Intrauterine Implants
      • 6.3.1.2. Prodrug Implants
      • 6.3.1.3. Polymeric Drug Delivery
      • 6.3.1.4. Targeted Drug Delivery
    • 6.3.2. Gene Delivery Systems
      • 6.3.2.1. Viral Gene Delivery
        • 6.3.2.1.1. Adenovirus Vector
        • 6.3.2.1.2. Lentivirus Vector
        • 6.3.2.1.3. Retrovirus Vector
        • 6.3.2.1.4. Adeno-associated Virus Vector
        • 6.3.2.1.5. Sendai Virus Vector
        • 6.3.2.1.6. Herpes Simplex Virus Vector
        • 6.3.2.1.7. Others
      • 6.3.2.2. Non-viral Gene Delivery
        • 6.3.2.2.1. Natural Organic Compounds
        • 6.3.2.2.2. Physical Methods
        • 6.3.2.2.3. Chemical Methods
      • 6.3.2.3. Combined Hybrid System
  • 6.4. Market Attractiveness Analysis, by Delivery System

7. Global Drug and Gene Delivery Systems Market Analysis and Forecast, by Route of Administration

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 7.3.1. Oral
    • 7.3.2. Injectable
    • 7.3.3. Inhalation
    • 7.3.4. Transdermal
    • 7.3.5. Ocular
    • 7.3.6. Nasal
    • 7.3.7. Topical
  • 7.4. Market Attractiveness Analysis, by Route of Administration

8. Global Drug and Gene Delivery Systems Market Analysis and Forecast, by Application

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Application, 2017-2031
    • 8.3.1. Infectious Diseases
    • 8.3.2. Oncology
    • 8.3.3. Ophthalmology
    • 8.3.4. Urology
    • 8.3.5. Diabetes
    • 8.3.6. CNS
    • 8.3.7. Others
  • 8.4. Market Attractiveness Analysis, by Application

9. Global Drug and Gene Delivery Systems Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region, 2017-2031
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. North America Drug and Gene Delivery Systems Market Analysis and Forecast

  • 10.1. Introduction
  • 10.2. Key Findings
  • 10.3. Market Value Forecast, by Delivery System, 2017-2031
    • 10.3.1. Drug Delivery Systems
      • 10.3.1.1. Intrauterine Implants
      • 10.3.1.2. Prodrug Implants
      • 10.3.1.3. Polymeric Drug Delivery
      • 10.3.1.4. Targeted Drug Delivery
    • 10.3.2. Gene Delivery Systems
      • 10.3.2.1. Viral Gene Delivery
        • 10.3.2.1.1. Adenovirus Vector
        • 10.3.2.1.2. Lentivirus Vector
        • 10.3.2.1.3. Retrovirus Vector
        • 10.3.2.1.4. Adeno-associated Virus Vector
        • 10.3.2.1.5. Sendai Virus Vector
        • 10.3.2.1.6. Herpes Simplex Virus Vector
        • 10.3.2.1.7. Others
      • 10.3.2.2. Non-viral Gene Delivery
        • 10.3.2.2.1. Natural Organic Compounds
        • 10.3.2.2.2. Physical Methods
        • 10.3.2.2.3. Chemical Methods
      • 10.3.2.3. Combined Hybrid System
  • 10.4. Market Value Forecast, by Route of Administration, 2017-2031
    • 10.4.1. Oral
    • 10.4.2. Injectable
    • 10.4.3. Inhalation
    • 10.4.4. Transdermal
    • 10.4.5. Ocular
    • 10.4.6. Nasal
    • 10.4.7. Topical
  • 10.5. Market Value Forecast, by Application, 2017-2031
    • 10.5.1. Infectious Diseases
    • 10.5.2. Oncology
    • 10.5.3. Ophthalmology
    • 10.5.4. Urology
    • 10.5.5. Diabetes
    • 10.5.6. CNS
    • 10.5.7. Others
  • 10.6. Market Value Forecast, by Country, 2017-2031
    • 10.6.1. U.S.
    • 10.6.2. Canada
  • 10.7. Market Attractiveness Analysis
    • 10.7.1. By Delivery System
    • 10.7.2. By Route of Administration
    • 10.7.3. By Application
    • 10.7.4. By Country

11. Europe Drug and Gene Delivery Systems Market Analysis and Forecast

  • 11.1. Introduction
  • 11.2. Key Findings
  • 11.3. Market Value Forecast, by Delivery System, 2017-2031
    • 11.3.1. Drug Delivery Systems
      • 11.3.1.1. Intrauterine Implants
      • 11.3.1.2. Prodrug Implants
      • 11.3.1.3. Polymeric Drug Delivery
      • 11.3.1.4. Targeted Drug Delivery
    • 11.3.2. Gene Delivery Systems
      • 11.3.2.1. Viral Gene Delivery
        • 11.3.2.1.1. Adenovirus Vector
        • 11.3.2.1.2. Lentivirus Vector
        • 11.3.2.1.3. Retrovirus Vector
        • 11.3.2.1.4. Adeno-associated Virus Vector
        • 11.3.2.1.5. Sendai Virus Vector
        • 11.3.2.1.6. Herpes Simplex Virus Vector
        • 11.3.2.1.7. Others
      • 11.3.2.2. Non-viral Gene Delivery
        • 11.3.2.2.1. Natural Organic Compounds
        • 11.3.2.2.2. Physical Methods
        • 11.3.2.2.3. Chemical Methods
      • 11.3.2.3. Combined Hybrid System
  • 11.4. Market Value Forecast, by Route of Administration, 2017-2031
    • 11.4.1. Oral
    • 11.4.2. Injectable
    • 11.4.3. Inhalation
    • 11.4.4. Transdermal
    • 11.4.5. Ocular
    • 11.4.6. Nasal
    • 11.4.7. Topical
  • 11.5. Market Value Forecast, by Application, 2017-2031
    • 11.5.1. Infectious Diseases
    • 11.5.2. Oncology
    • 11.5.3. Ophthalmology
    • 11.5.4. Urology
    • 11.5.5. Diabetes
    • 11.5.6. CNS
    • 11.5.7. Others
  • 11.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.6.1. Germany
    • 11.6.2. U.K.
    • 11.6.3. France
    • 11.6.4. Italy
    • 11.6.5. Spain
    • 11.6.6. Rest of Europe
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Delivery System
    • 11.7.2. By Route of Administration
    • 11.7.3. By Application
    • 11.7.4. By Country/Sub-region

12. Asia Pacific Drug and Gene Delivery Systems Market Analysis and Forecast

  • 12.1. Introduction
  • 12.2. Key Findings
  • 12.3. Market Value Forecast, by Delivery System, 2017-2031
    • 12.3.1. Drug Delivery Systems
      • 12.3.1.1. Intrauterine Implants
      • 12.3.1.2. Prodrug Implants
      • 12.3.1.3. Polymeric Drug Delivery
      • 12.3.1.4. Targeted Drug Delivery
    • 12.3.2. Gene Delivery Systems
      • 12.3.2.1. Viral Gene Delivery
        • 12.3.2.1.1. Adenovirus Vector
        • 12.3.2.1.2. Lentivirus Vector
        • 12.3.2.1.3. Retrovirus Vector
        • 12.3.2.1.4. Adeno-associated Virus Vector
        • 12.3.2.1.5. Sendai Virus Vector
        • 12.3.2.1.6. Herpes Simplex Virus Vector
        • 12.3.2.1.7. Others
      • 12.3.2.2. Non-viral Gene Delivery
        • 12.3.2.2.1. Natural Organic Compounds
        • 12.3.2.2.2. Physical Methods
        • 12.3.2.2.3. Chemical Methods
      • 12.3.2.3. Combined Hybrid System
  • 12.4. Market Value Forecast, by Route of Administration, 2017-2031
    • 12.4.1. Oral
    • 12.4.2. Injectable
    • 12.4.3. Inhalation
    • 12.4.4. Transdermal
    • 12.4.5. Ocular
    • 12.4.6. Nasal
    • 12.4.7. Topical
  • 12.5. Market Value Forecast, by Application, 2017-2031
    • 12.5.1. Infectious Diseases
    • 12.5.2. Oncology
    • 12.5.3. Ophthalmology
    • 12.5.4. Urology
    • 12.5.5. Diabetes
    • 12.5.6. CNS
    • 12.5.7. Others
  • 12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.6.1. China
    • 12.6.2. Japan
    • 12.6.3. India
    • 12.6.4. Australia & New Zealand
    • 12.6.5. Rest of Asia Pacific
  • 12.7. Market Attractiveness Analysis
    • 12.7.1. By Delivery System
    • 12.7.2. By Route of Administration
    • 12.7.3. By Application
    • 12.7.4. By Country/Sub-region

13. Latin America Drug and Gene Delivery Systems Market Analysis and Forecast

  • 13.1. Introduction
  • 13.2. Key Findings
  • 13.3. Market Value Forecast, by Delivery System, 2017-2031
    • 13.3.1. Drug Delivery Systems
      • 13.3.1.1. Intrauterine Implants
      • 13.3.1.2. Prodrug Implants
      • 13.3.1.3. Polymeric Drug Delivery
      • 13.3.1.4. Targeted Drug Delivery
    • 13.3.2. Gene Delivery Systems
      • 13.3.2.1. Viral Gene Delivery
        • 13.3.2.1.1. Adenovirus Vector
        • 13.3.2.1.2. Lentivirus Vector
        • 13.3.2.1.3. Retrovirus Vector
        • 13.3.2.1.4. Adeno-associated Virus Vector
        • 13.3.2.1.5. Sendai Virus Vector
        • 13.3.2.1.6. Herpes Simplex Virus Vector
        • 13.3.2.1.7. Others
      • 13.3.2.2. Non-viral Gene Delivery
        • 13.3.2.2.1. Natural Organic Compounds
        • 13.3.2.2.2. Physical Methods
        • 13.3.2.2.3. Chemical Methods
      • 13.3.2.3. Combined Hybrid System
  • 13.4. Market Value Forecast, by Route of Administration, 2017-2031
    • 13.4.1. Oral
    • 13.4.2. Injectable
    • 13.4.3. Inhalation
    • 13.4.4. Transdermal
    • 13.4.5. Ocular
    • 13.4.6. Nasal
    • 13.4.7. Topical
  • 13.5. Market Value Forecast, by Application, 2017-2031
    • 13.5.1. Infectious Diseases
    • 13.5.2. Oncology
    • 13.5.3. Ophthalmology
    • 13.5.4. Urology
    • 13.5.5. Diabetes
    • 13.5.6. CNS
    • 13.5.7. Others
  • 13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.6.1. Brazil
    • 13.6.2. Mexico
    • 13.6.3. Rest of Latin America
  • 13.7. Market Attractiveness Analysis
    • 13.7.1. By Delivery System
    • 13.7.2. By Route of Administration
    • 13.7.3. By Application
    • 13.7.4. By Country/Sub-region

14. Middle East & Africa Drug and Gene Delivery Systems Market Analysis and Forecast

  • 14.1. Introduction
  • 14.2. Key Findings
  • 14.3. Market Value Forecast, by Delivery System, 2017-2031
    • 14.3.1. Drug Delivery Systems
      • 14.3.1.1. Intrauterine Implants
      • 14.3.1.2. Prodrug Implants
      • 14.3.1.3. Polymeric Drug Delivery
      • 14.3.1.4. Targeted Drug Delivery
    • 14.3.2. Gene Delivery Systems
      • 14.3.2.1. Viral Gene Delivery
        • 14.3.2.1.1. Adenovirus Vector
        • 14.3.2.1.2. Lentivirus Vector
        • 14.3.2.1.3. Retrovirus Vector
        • 14.3.2.1.4. Adeno-associated Virus Vector
        • 14.3.2.1.5. Sendai Virus Vector
        • 14.3.2.1.6. Herpes Simplex Virus Vector
        • 14.3.2.1.7. Others
      • 14.3.2.2. Non-viral Gene Delivery
        • 14.3.2.2.1. Natural Organic Compounds
        • 14.3.2.2.2. Physical Methods
        • 14.3.2.2.3. Chemical Methods
      • 14.3.2.3. Combined Hybrid System
  • 14.4. Market Value Forecast, by Route of Administration, 2017-2031
    • 14.4.1. Oral
    • 14.4.2. Injectable
    • 14.4.3. Inhalation
    • 14.4.4. Transdermal
    • 14.4.5. Ocular
    • 14.4.6. Nasal
    • 14.4.7. Topical
  • 14.5. Market Value Forecast, by Application, 2017-2031
    • 14.5.1. Infectious Diseases
    • 14.5.2. Oncology
    • 14.5.3. Ophthalmology
    • 14.5.4. Urology
    • 14.5.5. Diabetes
    • 14.5.6. CNS
    • 14.5.7. Others
  • 14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.6.1. GCC Countries
    • 14.6.2. South Africa
    • 14.6.3. Rest of Middle East & Africa
  • 14.7. Market Attractiveness Analysis
    • 14.7.1. By Delivery System
    • 14.7.2. By Route of Administration
    • 14.7.3. By Application
    • 14.7.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
  • 15.2. Market Share Analysis, by Company (2022)
  • 15.3. Company Profiles
    • 15.3.1. Novartis AG
      • 15.3.1.1. Company Overview
      • 15.3.1.2. Delivery System Portfolio
      • 15.3.1.3. SWOT Analysis
      • 15.3.1.4. Financial Overview
      • 15.3.1.5. Strategic Overview
    • 15.3.2. Amgen Inc.
      • 15.3.2.1. Company Overview
      • 15.3.2.2. Delivery System Portfolio
      • 15.3.2.3. SWOT Analysis
      • 15.3.2.4. Financial Overview
      • 15.3.2.5. Strategic Overview
    • 15.3.3. Oxford BioMedica plc.
      • 15.3.3.1. Company Overview
      • 15.3.3.2. Delivery System Portfolio
      • 15.3.3.3. SWOT Analysis
      • 15.3.3.4. Financial Overview
      • 15.3.3.5. Strategic Overview
    • 15.3.4. SIBIONO
      • 15.3.4.1. Company Overview
      • 15.3.4.2. Delivery System Portfolio
      • 15.3.4.3. SWOT Analysis
      • 15.3.4.4. Financial Overview
      • 15.3.4.5. Strategic Overview
    • 15.3.5. Shanghai Sunway Biotech Co., Ltd.
      • 15.3.5.1. Company Overview
      • 15.3.5.2. Delivery System Portfolio
      • 15.3.5.3. SWOT Analysis
      • 15.3.5.4. Financial Overview
      • 15.3.5.5. Strategic Overview
    • 15.3.6. F. Hoffmann-La Roche Ltd.
      • 15.3.6.1. Company Overview
      • 15.3.6.2. Delivery System Portfolio
      • 15.3.6.3. SWOT Analysis
      • 15.3.6.4. Financial Overview
      • 15.3.6.5. Strategic Overview
    • 15.3.7. Pfizer, Inc.
      • 15.3.7.1. Company Overview
      • 15.3.7.2. Delivery System Portfolio
      • 15.3.7.3. SWOT Analysis
      • 15.3.7.4. Financial Overview
      • 15.3.7.5. Strategic Overview
    • 15.3.8. Bayer AG
      • 15.3.8.1. Company Overview
      • 15.3.8.2. Delivery System Portfolio
      • 15.3.8.3. SWOT Analysis
      • 15.3.8.4. Financial Overview
      • 15.3.8.5. Strategic Overview
    • 15.3.9. Johnson & Johnson Services, Inc.
      • 15.3.9.1. Company Overview
      • 15.3.9.2. Delivery System Portfolio
      • 15.3.9.3. SWOT Analysis
      • 15.3.9.4. Financial Overview
      • 15.3.9.5. Strategic Overview
    • 15.3.10. Becton, Dickinson and Company
      • 15.3.10.1. Company Overview
      • 15.3.10.2. Delivery System Portfolio
      • 15.3.10.3. SWOT Analysis
      • 15.3.10.4. Financial Overview
      • 15.3.10.5. Strategic Overview
    • 15.3.11. AstraZeneca plc
      • 15.3.11.1. Company Overview
      • 15.3.11.2. Delivery System Portfolio
      • 15.3.11.3. SWOT Analysis
      • 15.3.11.4. Financial Overview
      • 15.3.11.5. Strategic Overview
    • 15.3.12. Baxter International, Inc.
      • 15.3.12.1. Company Overview
      • 15.3.12.2. Delivery System Portfolio
      • 15.3.12.3. SWOT Analysis
      • 15.3.12.4. Financial Overview
      • 15.3.12.5. Strategic Overview
    • 15.3.13. Boston Scientific Corporation
      • 15.3.13.1. Company Overview
      • 15.3.13.2. Delivery System Portfolio
      • 15.3.13.3. SWOT Analysis
      • 15.3.13.4. Financial Overview
      • 15.3.13.5. Strategic Overview
    • 15.3.14. GenVivo, Inc.
      • 15.3.14.1. Company Overview
      • 15.3.14.2. Delivery System Portfolio
      • 15.3.14.3. SWOT Analysis
      • 15.3.14.4. Financial Overview
      • 15.3.14.5. Strategic Overview